With chronic cough ambitions, investors believe in Nocion

5 March 2024

US biopharma Nocion Therapeutics has raised $62 million in Series B funding.

Nocion is developing first and potentially best in class, small molecule, permanently charged sodium channel blockers (CSCBs), called nocions, that selectively silence activated nociceptors for the treatment of serious conditions involving cough, itch, and pain.

Proceeds from the financing will be used to evaluate the lead program, taplucanium dry powder for inhalation, in a Phase IIb study in chronic cough patients, and activities for Phase III readiness.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK